Ethex extends recall of oversized tablets
This article was originally published in Scrip
KV Pharmaceutical's Ethex generics division has expanded its recall of medicines that may contain oversized tablets with twice the intended level of active ingredient. Last month the company recalled three lots of dextroamphetamine 5mg tablets. The recall has now been extended to multiple lots of propafenone HCl 150mg, 225mg, and 300mg tablets; isosorbide mononitrate extended-release 30mg and 60mg tablets; morphine sulphate extended-release 15mg tablets; morphine sulphate immediate-release 15mg and 30mg tablets; and dextroamphetamine sulfate 10mg tablets. The products are being recalled to the consumer level, and Ethex is instructing pharmacies to contact consumers who were dispensed the drugs for replacement and/or refund.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.